Core Insights - Tilray Brands is a global leader in the medical cannabis industry, facing competition from major companies like Canopy Growth and Cronos Group [1] Summary by Sections Stock Performance - Bernstein maintained a "Market Perform" rating for Tilray, raising the price target from $1 to $10, while the stock was priced at $12.34 [2] - Despite the hold recommendation, Tilray's stock decreased by 4.2%, closing at $12.34, with trading volume surging to 66.7 million shares, a 514% increase from the three-month average of 10.9 million shares [3][6] - The stock fluctuated between $12.10 and $15.69 during the day, with a market capitalization of approximately $1.38 billion [5] Market Context - The broader market saw gains, with the S&P 500 rising by 0.79% and the Nasdaq Composite increasing by 1.38%, but not all cannabis stocks benefited, indicating market anticipation of the policy change [4][6] - Prior to the executive order reclassifying marijuana, Tilray's stock had surged over 50% due to rumors, which were confirmed by the order [4]

Tilray ( TLRY ) announced its entry into US cannabis markets today as Trump signed an EO to reschedule cannabis. The Executive Order directs the federal government to finish the process of reschedulingWelcome to the home of The Cannabis Report. I cover the cannabis sector and other sectors. I am most interested in technical stock analysis, option strategies, small cap strategies, and emerging markets. Feel free to contact me with any questions about publicly traded stocks in the cannabis industry.Analyst’s ...

President Donald Trump signed an executive order on Thursday, directing federal agencies to loosen regulations on marijuana, marking one of the most significant shifts in federal cannabis policy in decades.To Promote ‘Medical Uses’ of MarijuanaThe order directs U.S. Attorney General Pam Bondi to expedite the process of rescheduling marijuana to Schedule III under the Controlled Substances Act. This would put the popular psychoactive substance right alongside other common painkillers, which means it still fa ...

So joining us now is George Tillis, senior markets correspondent for the network. So George, we have seen some favorability from the Trump administration and that's led to I mean a recent really uptick in a lot of these names, but volatile space still I think the federal overall just you know legalization is in question but walk us through the story. Yeah.So, you know, we we talk about a lot of times these changes in in laws uh you know, especially around laws regarding legalization of marijuana. Also, righ ...

Global Cannabis Leader Poised for Major U.S. Market Entry, Signaling New Era for HealthcareNEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis healthcare, today confirmed its planned strategic framework to advance its U.S. medical cannabis operations following federal cannabis rescheduling and related regulatory developments. In conjunction with these regulatory changes, Ti ...

U.S. President Donald Trump sits in the Oval Office to sign executive orders, at the White House in Washington, D.C., U.S., Dec. 18, 2025.President Donald Trump signed an executive order Thursday directing federal agencies to reclassify marijuana, loosening long-standing restrictions on the drug and marking the most consequential shift in U.S. cannabis policy in more than half a century.The order, once finalized by the Drug Enforcement Administration, moves cannabis out of Schedule I classification — the mo ...

We came across a bearish thesis on Tilray Brands, Inc. on The Dutch Investors’s Substack. In this article, we will summarize the bulls’ thesis on TLRY. Tilray Brands, Inc.'s share was trading at $12.88 as of December 18th. TLRY’s trailing P/E was 57.50 according to Yahoo Finance. Top 20 Countries With The Highest Weed Consumption Top 20 Countries With The Highest Weed Consumption Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distributio ...

Tilray stock price popped by nearly 30% on Tuesday as Donald Trump prepared to sign an executive order that would reschedule cannabis into a lower drug classification. It jumped to a high of $14.40, u... ...

Shares of publicly traded companies operating in the cannabis space continue to perform strongly as the Trump administration considers reclassifying marijuana. Reports first emerged last week that the Trump administration might change marijuana from a Schedule I drug to a Schedule III drug, which would lessen restrictions on it. Cresco Labs Inc (OTCQX: CRLBF) On Monday, President Trump told reporters that he was "considering†the reclassification. "We are considering that because a lot of people want to see ...

The U.S. labor market showed further signs of cooling in November as nonfarm payrolls rose by 64,000, only modestly above expectations but still weak by historical standards, while the unemployment rate unexpectedly climbed to 4.6%,The Dow Jones Industrial Average fell 0.6% to 48,114.26, while the S&P 500 dropped 0.2% to 6,800.26. The Nasdaq rose 0.2% to 23,111.46.These are the top stocks that gained the attention of retail traders and investors through the day.Tilray Brands Inc. (NASDAQ:TLRY) Tilray Brands ...